Turnstone raises C$11.3M series A

Turnstone Biologics Inc. (Toronto, Ontario) raised C$11.3 million ($8.6 million) in a series A round led by Versant Ventures. Turnstone is developing oncolytic Maraba virus immunotherapies that are engineered to express tumor antigens. The company's unnamed lead product expresses melanoma-associated antigen A3 ( MAGEA3) and is in Phase I/II testing to treat advanced or metastatic solid tumors that express the antigen. ...